Assessing Health-Related Quality of Life and Willingness to Pay for Weight Management in Asia-Pacific by Gender (ASPECT - APAC)

February 7, 2024 updated by: Novo Nordisk A/S
The purpose of this survey is to collect information for scientific research and to identify the impact of overweight and obesity on health-related quality of life.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Actual)

3000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Adults recruited to complete self-administered online service

Description

Inclusion Criteria:

  1. Informed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol).
  2. Male or female, age above or equal to 18 years at the time of signing informed consent.
  3. Not currently pregnant
  4. Does not participate in intense fitness or body building program
  5. Weight loss not through illness or injury
  6. Lives in South Korea, Australia, or India
  7. BMI above or equal to 18 and associated weight class (Normal Weight or above) will be determined by a programmed calculation based on participant-reported height and weight.

Exclusion Criteria:

  1. Previous participation in this study. Participation is defined as having given informed consent in this study
  2. Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation
  3. Does not meet inclusion criteria.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Normal weight
Adults with normal weight, recruited to complete self-administered online service
Other: No treatment is given
No treatment is given
Overweight
Adults with overweight, recruited to complete self-administered online service
Other: No treatment is given
No treatment is given
Obesity Class I
Adults with obesity class I, recruited to complete self-administered online service
Other: No treatment is given
No treatment is given
Obesity Class II
Adults with obesity class II, recruited to complete self-administered online service
Other: No treatment is given
No treatment is given
Obesity Class III
Adults with obesity class III, recruited to complete self-administered online service
Other: No treatment is given
No treatment is given

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Score on IWQOL-Lite validated
Time Frame: At time of survey response (Day 1)
Calculated score. Likert scale; 1=Never True, 5=Always True
At time of survey response (Day 1)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Novo Nordisk A/S

Investigators

  • Study Director: Clinical Transparency (dept. 2834), Novo Nordisk A/S

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 10, 2023

Primary Completion (Actual)

October 5, 2023

Study Completion (Actual)

October 5, 2023

Study Registration Dates

First Submitted

February 7, 2024

First Submitted That Met QC Criteria

February 7, 2024

First Posted (Actual)

February 15, 2024

Study Record Updates

Last Update Posted (Actual)

February 15, 2024

Last Update Submitted That Met QC Criteria

February 7, 2024

Last Verified

February 1, 2024

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • DAS-7626
  • U1111-1282-5512 (Other Identifier: World Health Organization (WHO))

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Drug and device information, study documents

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Obesity

Clinical Trials on No treatment is given

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Madagascar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe